share_log

Intelligent Bio Solutions | S-3: Registration statement for specified transactions by certain issuers

Intelligent Bio Solutions | S-3:特定交易注册声明

美股sec公告 ·  03/04 17:32
Moomoo AI 已提取核心信息
Intelligent Bio Solutions Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on March 4, 2024, to register shares for potential future sale. This registration statement pertains to the resale of up to 636,367 shares of common stock, which may be issued upon the exercise of certain Series G Warrants and Placement Agent Warrants. The Series G Warrants were issued to certain selling stockholders in exchange for their exercise of existing Series E Warrants, and the Placement Agent Warrants were issued to Ladenburg Thalmann & Co. Inc., the placement agent for the issuance of the Inducement Warrants. The company will not receive any proceeds from the sale of shares by the selling stockholders but will receive the exercise price if...Show More
Intelligent Bio Solutions Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on March 4, 2024, to register shares for potential future sale. This registration statement pertains to the resale of up to 636,367 shares of common stock, which may be issued upon the exercise of certain Series G Warrants and Placement Agent Warrants. The Series G Warrants were issued to certain selling stockholders in exchange for their exercise of existing Series E Warrants, and the Placement Agent Warrants were issued to Ladenburg Thalmann & Co. Inc., the placement agent for the issuance of the Inducement Warrants. The company will not receive any proceeds from the sale of shares by the selling stockholders but will receive the exercise price if the warrants are exercised for cash. The registration allows the selling stockholders to sell their shares from time to time in the public market, through private transactions, or otherwise, at prevailing market prices or at negotiated prices. Intelligent Bio Solutions Inc. has agreed to keep the prospectus effective until all registered shares are sold or the offering is otherwise completed. The company has also entered into indemnification agreements with its directors and officers, and its bylaws provide for indemnification to the fullest extent permitted by Delaware law.
Intelligent Bio Solutions Inc.已于2024年3月4日向美国证券交易委员会(SEC)提交了S-3表格,要求注册股票以备将来可能出售。本注册声明涉及最多636,367股普通股的转售,这些普通股可以在行使某些G系列认股权证和配售代理认股权证时发行。G系列认股权证是向某些出售股东发行的,以换取他们行使现有的E系列认股权证,配售代理认股权证是向拉登堡塔尔曼公司发行的。Inc.,发行激励认股权证的配售代理。该公司不会从出售股东出售股票中获得任何收益,但如果认股权证以现金行使,则将获得行使价。注册允许出售股东不时在公开市场上,通过私下交易或其他方式,以现行市场价格或协议价格出售其股票。Intelligent Bio Solutions Inc.已同意在出售所有注册股票或以其他方式完成发行之前保持招股说明书的有效性。该公司还与其董事和高级管理人员签订了赔偿协议,其章程规定在特拉华州法律允许的最大范围内进行赔偿。
Intelligent Bio Solutions Inc.已于2024年3月4日向美国证券交易委员会(SEC)提交了S-3表格,要求注册股票以备将来可能出售。本注册声明涉及最多636,367股普通股的转售,这些普通股可以在行使某些G系列认股权证和配售代理认股权证时发行。G系列认股权证是向某些出售股东发行的,以换取他们行使现有的E系列认股权证,配售代理认股权证是向拉登堡塔尔曼公司发行的。Inc.,发行激励认股权证的配售代理。该公司不会从出售股东出售股票中获得任何收益,但如果认股权证以现金行使,则将获得行使价。注册允许出售股东不时在公开市场上,通过私下交易或其他方式,以现行市场价格或协议价格出售其股票。Intelligent Bio Solutions Inc.已同意在出售所有注册股票或以其他方式完成发行之前保持招股说明书的有效性。该公司还与其董事和高级管理人员签订了赔偿协议,其章程规定在特拉华州法律允许的最大范围内进行赔偿。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息